Home > Insider Trading > Filing (0001654954-24-010192)

Filing Details

Accession Number:: 0001654954-24-010192
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-08-08 19:42:23
Reporting Period:: 2024-08-08

Accepted Time:: 2024-08-08 19:42:23
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
34956	Tenax Therapeutics Inc.	TENX	Pharmaceutical Preparations (2834)	262593535

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1573785	H. Michael Davidson	101 Glen Lennox Drive, Suite 300 Chapel Hill NC 27517		No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-08-08	2,500	$0.00	2,881	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Pre-Funded Warrant	Acquisiton	2024-08-08	47,500	$0.00	47,500	$0.01
Common Stock	Warrant	Acquisiton	2024-08-08	25,000	$0.00	25,000	$4.50

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
47,500	2024-08-08		No	4	P	Direct
25,000	2024-08-08		No	4	P	Direct

Reported Derivative Holdings

Show Other Fields >>

Sec. Name	Sec. Type	Price	Date	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock	Stock Option (right to buy)	$992.00	2023-06-09	2032-06-09	4	4	Direct
Common Stock	Stock Option (right to buy)	$3,200.00	2022-06-10	2032-06-10	4	4	Direct

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2032-06-09	4	4	Direct
2032-06-10	4	4	Direct

Footnotes

. On August 8, 2024, as part of a private placement of the Issuer's securities, the Reporting Person purchased shares of the Issuer's common stock ("Shares") and a pre-funded warrant to purchase Shares, along with a warrant to purchase Shares, pursuant to the terms of a Securities Purchase Agreement, dated August 6, 2024, by and among the Issuer, Reporting Person and certain other accredited investors. The purchase price for each Share and accompanying warrant (reported in Table II) is $3.00. The purchase price for each pre-funded warrant and accompanying warrant (reported in Table II) is $2.99.
The aggregate number of shares of common stock previously reported as 608,645, but were adjusted to reflect the stock splits that occurred on January 4, 2023 and January 2, 2024.
The pre-funded warrant has no expiration date.
The warrant will expire on the earlier of (i) thirty (30) trading days following the date of the Issuer's initial public announcement of topline data from its Phase 3 LEVEL Study (LEVosimendan to Improve Exercise Limitation in PH-HFpEF Patients) ( NCT05983250 ) (the "Topline Data Announcement"); (ii) proportionally upon the exercise of the Reporting Person's pre-funded warrant issued on August 8, 2024, if such exercise is prior to the Topline Data Announcement; and (iii) August 8, 2029.
These options were previously reported as covering 5,000 shares at an exercise price of $0.62 per share, but were adjusted to reflect the stock splits that occurred on January 4, 2023 and January 2, 2024.
These options were previously reported as covering 6,250 shares at an exercise price of $2.00 per share, but were adjusted to reflect the stock splits that occurred on January 4, 2023 and January 2, 2024.